These findings encourage researchers to further confirm the tumor response of cellular vaccines based on specific molecular subtypes in the ongoing larger randomized trials, such as IDH1 R132H-DC vaccine (NCT02771301), which may provide the hope to optimize cellular vaccines in gliomas. Here, IDH1 is linked to glioma.